The effect of cardioprotectors on protease-іnhіbіtory potentіal in blood and heart of rats with epinephrine-induced myocardial ischemia

V. Paronik; O. Shaul’s’ka; L. Diachenko; A. Shevtsova

doi:10.15421/021605

V. Paronik Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine
O. Shaul’s’ka Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine
L. Diachenko Dnipropetrovsk State Agrarian and Economic University
A. Shevtsova Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine

Keywords: epinephrine-induced myocardial ischemia, inhibitors of proteolysis, matrix metallopreoteinases, cardioprotectors

Abstract

Coronary heart disease is one of the major causes of illness and of deaths in Europe, therefore the definition of the signaling pathways involved in cardioprotection represents a challenging goal in order to discover novel pharmacological approaches. One of the mechanisms included in the implementation of signaling methods is proteolysis, so the aim of our study was to study the balance between activity of the proteolytic enzymes and their inhibitors in the experimental myocardial ischemia of rats and the impact of corvitin (C) and doxycycline (D) on these parameters. Ischemia was induced in Wistar rats by the intraperitoneal injection of epinephrine at a dose of 0.2 mg/100 g of weight during 10 days. All animals were divided into 4 groups: 1 – control (8 rats), 2 – rats with epinephrine-induced myocardial ischemia (EIM, n = 10), 3 – rats, which were entered C after completion of epinephrine injections (n = 10), 4 – rats, which accepted D during 6 days after finishing of epinephrine injections (n = 10). The electrical activity of the heart was recorded on an electrocardiogram (ECG). Activities of matrix metalloproteinases 2 and 9 (MMP2, MMP9) were studied by enzyme-zymography, the activity of trypsin-like enzymes (TLE), levels of alpha-1 proteinase inhibitor (IP1) and alpha-2-macroglobulin (α2-МG) in the blood and the heart were determined by spectrophotometric methods. The experimental results suggest that epinephrine injections lead to changes in the ECG typical for ischemic myocardium. The data obtained showed that the protease-іnhіbіtory balance in the blood and in heart was disturbed. Activity of MMP9, proMMP9/2 and level of IP1 increased in blood plasma of rats with EIM, but activities of ММP2, TLE were unchanged in this group. In the heart muscle the activity of MMP2 and level of IP1 increased. Administration of C resulted in the recovery of MMPs level, but disturbed the balance in the system TLE/IP1-α2-МG. Administration of D blocked the activity of MMP9, significantly reduced the activity of MMP2, which testifies the inhibitory effect of this drug on the activity of matrix metalloproteinases. Based on these results, we conclude that definition of protease-inhibitory balance in the blood plasma of patients with coronary artery disease is promising as an additional diagnostic complex and for monitoring of the effectiveness of therapy.

References

Aljavi, A.L., Kenzhaev, M.L., Haitov, S.S., Kenzhaev, S.R., 2012. Profilaktika diastolicheskoj disfunkcii levogo zheludochka pri ostrom koronarnom syndrome s jelevaciej segmenta ST [Prevention of left ventricular diastolic dysfunction in acute coronary syndrome with ST segment elevation]. Ukr. Medichnij Chasopis 88, (in Ukrainian).

Baggen,V.J., Eindhoven, J.A., van den Bosch, A.E., Witsenburg, M., Cuypers, J.A., Langstraat, J.S., Boersma, E., Roos-Hesselink, J.W., 2016. Matrix metalloproteinases as candidate biomarkers in a dults with congenital heart disease. Biomarkers 17, 1–8.

Cerisano, G., Buonamici, P., Valenti, R., Moschi, G., Taddeucci, E., Giurlani, L., Migliorini, A., Vergara, R., Parodi, G., Sciagrà, R., Romito, R., Colonna, P., Antoniucci, D., 2014. Effects of a timely therapy with doxycycline on the left ventricular remodeling according to the pre-procedural TIMI flow grade in patients with ST-elevation acute myocardial infarction. Basic. Res. Cardiol. 109(4), 412. >> doi:10.1007/s00395-014-0412-2

Deleon-Pennell, K.Y., Altara, R., Yabluchanskiy, A., Modesti, A., Lindsey, M.L. 2015. The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial. IUBMB Life 67(8), 611–618.

Hidirova, L.D., 2010. Izmenenie balansa mezhdu aktivnost’ju perekisnogo okislenija lipidov, antioksidantnoj zashhitoj i soderzhaniem zheleza u krys pri jeksperimental’nom infarkte miokarda [Change in balance between activity of lipid peroxidation, antioxidant system and ferrum content in rats with experimental myocardial infarction]. Racional’naja Farmakoterapija v Kardiologii 6(2), 216–219 (in Russian).

Horwitz, V., Dachir, S., Cohen, M., Gutman, H., Cohen, L., Fishbine, E., Brandeis, R., Turetz, J., Amir, A., Gore, A., Kadar, T., 2014. The beneficial effects of doxycycline, an inhibitor of matrix metalloproteinases, on sulfur mustard-induced ocular pathologies depend on the injury stage. Curr. Eye. Res. 39(8), 803–812. >> doi:10.3109/02713683.2013.874443

Hushmatov, S.S., Mahmudov, R.R., Mavljanov, S.M., 2015. Sravnitel’noe izuchenie inotropnoj i antiaritmicheskoj aktivnosti flavonoidov – kvercetina, rutina i (+) – katehina [Comparison of inotropic and antiarrhythmic activity of flavonoids – quercetin, rutin and (+) – catechin]. Rossijskij Kardiologicheskij Zhurnal 11, 35–41 (in Russian).

Karkischenko, N.N., Gracheva, S.V., 2010. Rukovodstvo po laboratornym zhivotnym i al’ternativnym modeljam v biomedicinskih tehnologijah [The guidance for laboratory animals and alternative models in biomedical technology]. Alternatives of Biomedicine, Moscow (in Russian).

Lizotte-Waniewski, M., Brew, K., Hennekens, C.H., 2015. Hypothesis: Metalloproteinase inhibitors decrease risks of cardiovascular disease. J. Cardiovasc. Pharmacol. Ther. pii: 1074248415615237.

Malik, Y.S., Sheikh, M.A., Zhu, X., 2013. Doxycycline can stimulate cytoprotection in neural stem cells with oxygen-glucose deprivation-reoxygenation injury: A potential approach to enhance effectiveness of cell transplantation therapy. Biochem. Biophys. Res. Commun. 432(2), 355–358.

Münch, J., Avanesov, M., Bannas, P., Säring, D., Krämer, E., Mearini, G., Carrier, L., Suling, A., Lund, G., Patten, M., 2016. Serum matrix metalloproteinasesas quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy. J. Card. Fail. S1071-9164(16)00101-9.

Oliveira, H.L., Tedesco, T.K., Rodrigues-Filho, L.E., Soares, F.Z., Rocha, R.O., 2016. Doxycycline as a matrix metalloproteinase inhibitor to prevent bond degradation: The effect of acid and neutral solutions on dentin bond strength. Gen. Dent. 64(2), 14–17.

Ortiz-Vilchis, P., Yamazaki, K.G., Rubio-Gayosso, I., Ramirez-Sanchez, I., Calzada, C., Romero-Perez, D., Ortiz, A., Meaney, E., Taub, P., Villarreal, F., Ceballos, G., 2014. Co-administration of the flavanol (-)-epicatechin with doxycycline synergistically reduces infarct size in a model of ischemia reperfusion injury by inhibition of mitochondrial swelling. Eur. J. Pharmacol. 744, 76–82. >> doi:10.1016/j.ejphar.2014.09.042

Ozcinar, E., Okatan, E.N., Tuncay, E., Eryilmaz, S., Turan, B., 2014. Improvement of functional recovery of donor heart following cold static storage with doxycycline cardioplegia. Cardiovasc. Toxicol. 14(1), 64–73.

Parhomenko, A.N., Kozhuhov, S.N., 2004. Kardioprotekcija pri ostrom infarkte miokarda: Teoreticheskie predposylki i vozmozhnye puti klinicheskogo reshenija problemy [Cardioprotection in acute myocardial infarction: Theoretical pre-requisites and possible ways of clinical solution of the problem]. Kardiologija 2, 6–11 (in Russian).

Paronik, V.A., Shaul’s’ka, O.E., Zhylyuk, V.I., Shevtsova, A.I., 2015. Activnist׳ antyoksydantnykh fermentiv ta zheltynaz za adrenalinovoyi ishemiyi miokarda u shchuriv [Activity of antioxidant enzymes and gelatinases in rats with epinephrine-iduced myocardial ischemia]. Medychna ta Klinichna Biokhimiya 3, 71–75 (in Ukrainian).

Rodriguez-Granillo, G.A., Rodriguez-Granillo, A., Milei, J., 2011. Effect of doxycycline on atherosclerosis: From bench tobedside. Recent Pat. Cardiovasc. Drug Discov. 6(1), 42–54.

Schulze, C.J., Castro, M.M., Kandasamy, A.D., Cena, J., Bryden, C., Wang, S.H., Koshal, A., Tsuyuki, R.T., Finegan, B.A., Schulz, R., 2013. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass. Crit. Care Med. 41(11), 2512–2520. >> doi:10.1097/CCM.0b013e318292373c

Testai, L., 2015. Flavonoids and mitochondrial pharmacology: A new paradigm for cardioprotection. Life Sci. 135, 68–76. >> doi:10.1016/j.lfs.2015.04.017

Vélez, P., Parguiña, A.F., Ocaranza-Sánchez, R., Grigorian-Shamagian, L., Rosa, I., Alonso-Orgaz, S., dela Cuesta, F., Guitián, E., Moreu, J., Barderas, M.G., González-Juanatey, J.R., García, Á., 2014. Identification of a circulating microvesicle protein network in volvedin ST-elevation myocardial infarction. Thromb. Haemost. 112(4), 716–726.

Veremeenko, K.N., Goloborod’ko, O.P., Kizim, A.I., 1988. Proteoliz v norme i pri patologii. Zdorovja, Kiev (in Russian).

Yang, S., Chen, L., Sun, S., Shah, P., Yang, W., Zhang, B., Zhang, Z., Chan, D.W., Kass, D.A., van Eyk, J.E., Zhang, H., 2015. Glycoproteins identified from heart failure and treatment models. Proteomics 15, 567–579. >> doi:10.1002/pmic.201400151